Endocrine Abstracts

Background: Bone mass is low and fracture risk is higher in obese children. We wished to ascertain the relationships of obesity-related changes in hormones with skeletal microstructure.Method: Children aged 8–15 years matched by gender and pubertal stage were recruited into lean and obese groups (18 pairs). We used high resolution peripheral quantitative computed tomography (HRpQCT – resolution-82 μm) to assess three-dimensional cortical a...

Introduction: There is a rare but well documented association between thymic hyperplasia and Graves’ disease particularly in young patients. It is important to recognise this as patients presenting with an anterior mediastinal mass will often undergo extensive investigations to exclude an underlying lymphoproliferative disorder.Case study: A 19-year-old female with symptomatic Graves’ thyrotoxicosis (TSH <0.01 mU/l; FT4 46.8 pmol...

Introduction: Effective transition care is vital to empower young people (YP) to optimally self-manage their diabetes. National data highlights the concern regarding poorer care outcomes due to lower completion of annual care processes and higher rates of DKA whilst transitioning to adult care. The Children and Young People’s Diabetes Team provides care for 170 YP aged 16–19 years. In April 2017, 19% of this age group had a HbA1c <58 mmol/mol, significantly lower...

Background: Over-dosing and under-dosing of vitamin D in children and young people appears to be common, based on our audit of current practice. The contribution of ethnicity, skin colour, and vitamin D binding protein (VDBP) genotype has not been fully explored during vitamin D treatment.Objective: To investigate how ethnicity/skin colour and genetic variation affect the response to 150 000 units of vitamin D administered to young adults of white Caucas...

Background: The role of bisphosphonates in improving bone mass in patients with osteogenesis impefercta (OI) is well established. However, the impact of bisphosphonate therapy on body composition in relation to increasing bone mass remains relatively unexplored.Methods: Change in DXA-derived subtotal body (TBLH) and lumbar spine (LS: L1–L4) bone mineral content (BMC (g)), bone area (BA (cm2)), areal bone mineral density (aBMD (g/cm2<...

Introduction: Adults with Type 1 Diabetes Mellitus (T1DM) are at risk of premature osteoporosis and fractures. The onset of T1DM typically starts during childhood and adolescence thus the effects of diabetes on the skeleton may be established in this period. Studies in children primarily use DXA to evaluate the effects of T1DM on bone with conflicting results. We present the first study in children assessing the impact of T1DM on skeletal microstructure and strength, using HRp...

Background: Puberty is understood to be commonly affected in adolescents with Crohn’s disease (CD) and ulcerative colitis (UC).Objective: To determine the impact of IBD on pubertal status and pubertal growth.Methods: Single centre prospective study over 12 months of 45 adolescents (boys, 23) with CD and 18 (boys, 12) with UC with a median age of 13.4 years (10, 16.6). Assessment included details of disease, anthropometry and b...

Background: Delayed puberty and related problems with growth and body image in Crohn’s disease (CD) and ulcerative colitis (UC) have rarely been quantified.Methods: A longitudinal prospective observational study of children with IBD who had anthropometric and puberty data at 0 and 6 months. Of 50 recruited, there were 15 boys (CDM) and 20 girls (CDF) with CD and ten boys (UCM) and five girls (UCF) with UC. The four groups had a median age at 0 month...

Background: Puberty is understood to be commonly effected in adolescents with Crohn’s Disease (CD) and ulcerative colitis (UC). However, the extent of this effect and related problems with growth, have rarely been quantified.Objective: To determine the impact of CD and UC on pubertal growth.Methods: Retrospective study of 148 children with IBD (casenotes available, 135) who fulfilled the criteria for describing growth spurt pa...

Introduction: Treatment with anti-TNFα therapy such as infliximab may improve growth in children with CD but the extent of improvement in growth and its relationship to pubertal progress and changes in glucocorticoid therapy are unclear.Aim: A retrospective study of growth, puberty and disease activity over the 6 months prior (T−6) to starting infliximab, at baseline (T0) and for the following 6 months (T+6) in CD. Results are expressed as med...